value
| - PURPOSE: Our objective was to evaluate the influence of pre-treatment with tocilizumab (TCZ) in bone healing after tooth extraction in rats. METHODS: Wistar male rats were equally divided into sham (i.e., non-operated), saline (both treated with 0.1 ml/kg saline), and six TCZ groups treated with 1, 2, 4, 8, 16, and 32 mg/kg TCZ (TCZ1 to TCZ32, respectively). Twenty-four hours after administration of vehicle or TCZ, exodontia of the first lower left molar was performed, and the animals were euthanized three days later for hematological analysis and organ (liver, spleen, and kidney mass indexes, and histological evaluation), gingiva (myeloperoxidase [MPO] assay), and mandible (radiographic, histomorphometric analysis, and IL-6 immunostaining) evaluation. Analysis of variance/Bonferroni test (statistical significance, p<0.05) was performed using GraphPad Prism version 5.0 (GraphPad Inc, San Diego, CA, USA). RESULTS: There was no difference in radiographic results; however, leukopenia (p=0.039) and neutropenia (p<0.001) were statistically significant in the TCZ16 and TCZ32 groups. Weight loss (p<0.001) and reduced liver index (p=0.001) were significantly dose dependent; however, no histological alterations were observed in the other organs. Osteoclast counts were reduced in groups TCZ4 to TCZ32 (p<0.001), and IL-6 immunostaining increased in the TCZ8 to TCZ32 groups (p<0.001). Alveolar infection rates increased in groups TCZ4 to TCZ32 (p<0.001), and MPO had biphasic response, exhibiting a reduction in groups TCZ2 and TCZ4, and an increase in group TCZ32 (p=0.004). CONCLUSION: TCZ-induced immunosuppression led to a reduction in osteoclast function, an increase in alveolar infection, and compensatory neutrophil infiltration.
|